In Vivo Measurement of Vesicular Monoamine Transporter Type 2 Density in Parkinson Disease With 18f-Av-133

Journal of Nuclear Medicine - China
doi 10.2967/jnumed.109.070094
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Society of Nuclear Medicine

Related search

In Vivo Assessment of Vesicular Monoamine Transporter Type 2 in Dementia With Lewy Bodies and Alzheimer Disease

Archives of Neurology
2011English

Ephedrine Decreases Vesicular Monoamine Transporter-2 Function

Synapse
Molecular NeuroscienceCellular
2011English

Genetic Variation in the Vesicular Monoamine Transporter

Journal of Head Trauma Rehabilitation
Physical TherapySports TherapyNeurologyRehabilitation
2017English

The Vesicular Monoamine Transporter 2: An Underexplored Pharmacological Target

Neurochemistry International
Molecular NeuroscienceCell BiologyCellular
2014English

A Novel Potential Positron Emission Tomography Imaging Agent for Vesicular Monoamine Transporter Type 2

PLoS ONE
Multidisciplinary
2016English

Characterization of [11C]tetrabenazine as an in Vivo Radioligand for the Vesicular Monoamine Transporter

Nuclear Medicine and Biology
Cancer ResearchNuclear MedicineRadiologyMolecular MedicineImaging
1994English

Lobelane Analogues as Novel Ligands for the Vesicular Monoamine Transporter-2

Bioorganic and Medicinal Chemistry
Organic ChemistryMolecular MedicineMolecular BiologyBiochemistryClinical BiochemistryPharmaceutical ScienceDrug Discovery
2005English

Therapeutic Doses of Amphetamine and Methylphenidate Selectively Redistribute the Vesicular Monoamine Transporter-2

European Journal of Pharmacology
Pharmacology
2007English

Identification of Residues Involved in Substrate Recognition by a Vesicular Monoamine Transporter

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
1995English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy